Hematological Dynamic Scores for Predicting Survival and Treatment Response for Advanced Gastric Cancer After Neoadjuvant Therapy

NCT06573307 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 442

Last updated 2024-08-27

No results posted yet for this study

Summary

HMDLS, based on hematological markers, could effectively distinguish the long-term efficacy of AGC patients after NAT. The predictive performance of nomogram-HMDLS was better than ypTNM stage, achieving better prognostic stratification and tumor treatment response prediction.

Conditions

Sponsors & Collaborators

  • Chang-Ming Huang, Prof.

    lead OTHER

Principal Investigators

  • Changming Huang · Fujian Medical University Union Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-10
Primary Completion
2024-08-10
Completion
2024-08-26

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06573307 on ClinicalTrials.gov